{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:13:16Z","timestamp":1789193596905,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Haemoglobin SC (HbSC) disease is the second most prevalent form of sickle cell disease, but evidence for hydroxyurea (hydroxycarbamide; HU) to prevent pain episodes was limited until the prospective identification of variables as outcomes for treatment (PIVOT) trial. To assess HU effectiveness and safety in adults with HbSC, we conducted a retrospective, single\u2010centre, pre\u2013post cohort study at the Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al. Patients initiated HU between January 2010 and July 2025. Effectiveness analysis required \u226512\u2009months of pre\u2010HU follow\u2010up; patients with shorter follow\u2010up were included for the safety analysis only. The primary end\u2010point was the change in the annual frequency of a vaso\u2010occlusive crisis (VOC) composite (VOCC: VOC, acute chest syndrome, priapism, splenic\/hepatic sequestration) from 12\u2009months pre\u2010HU to months 4\u201316 post\u2010HU. Secondary end\u2010points included adverse events (AEs), treatment effectiveness and reasons for HU discontinuation. Of 263 patients assessed, 110 were included in the safety analysis and 75 in the effectiveness analysis. HU reduced mean VOCC by 56% (0.57\u20130.25; \u0394\u2009=\u2009\u22120.32\u2009\u00b1\u20090.84; 95% confidence interval [CI] [\u22120.51, \u22120.13];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0015). Haematological AEs were mostly mild (thrombocytopenia, 32.7%; neutropenia, 23.6%; leucopenia, 20.9%); bilirubin elevations were the most frequent non\u2010haematological AE (10.9%), all asymptomatic and without clinical hepatotoxicity. In conclusion, HU was associated with a meaningful reduction in VOCC and was generally well tolerated.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70622","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:40:07Z","timestamp":1782484807000},"page":"1291-1300","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin\n                    <scp>SC<\/scp>\n                    disease: A real\u2010world study in Quebec"],"prefix":"10.1111","volume":"209","author":[{"given":"Alice","family":"Girard","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 of Montr\u00e9al  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurianne","family":"Charette","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 of Montr\u00e9al  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lissa","family":"Haouchine","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 of Montr\u00e9al  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bozec","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 of Montr\u00e9al  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Zakaria Bachir","family":"Bouyadjera","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 of Montr\u00e9al  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane","family":"Poitras","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent\u2010Thierry","family":"Taillefer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Trudeau","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"},{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Pastore","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Centre Hospitalier Universitaire Sainte\u2010Justine  Montr\u00e9al Canada"},{"name":"Department of Medicine Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"},{"name":"Department of Medicine Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Letarte","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Universit\u00e9 of Montr\u00e9al  Montr\u00e9al Canada"},{"name":"Department of Pharmacy Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"},{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-9234","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Fort\u00e9","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"},{"name":"Department of Medicine Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"},{"name":"Department of Medicine Universit\u00e9 de Montr\u00e9al  Montr\u00e9al Canada"},{"name":"Department of Paediatrics Centre de Recherche Azrieli du CHU Sainte Justine  Montr\u00e9al Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"CHUM.Rare Disease Day: Sickle cell anaemia and COVID\u201019 a risky cocktail. Available from:https:\/\/www.chumontreal.qc.ca\/actualites\/journee\u2010internationale\u2010maladies\u2010rares\u2010anemie\u2010falciforme\u2010covid\u201019\u2010cocktail\u2010risque. Accessed October 14 2025."},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/pxab096"},{"key":"e_1_2_13_4_1","unstructured":"ASH.ASH SCD Guidelines: Management of Acute and Chronic Pain. Available from:https:\/\/www.hematology.org\/education\/clinicians\/guidelines\u2010and\u2010quality\u2010care\/clinical\u2010practice\u2010guidelines\/scd\u2010guidelines\u2010management\u2010of\u2010acute\u2010and\u2010chronic\u2010pain. Accessed October 14 2025."},{"key":"e_1_2_13_5_1","unstructured":"Association CH.Consensus Statement on the Care of Patients with Sickle Cell Disease in Canada. Version 2.0. Available from:https:\/\/canhaem.org\/wp\u2010content\/uploads\/2025\/06\/CanHaem\u2010SCD\u2010Consensus\u2010Statement\u2010intro.pdf."},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002202.pub3"},{"key":"e_1_2_13_7_1","unstructured":"Clinic C.Sickle Cell Disease. Available from:https:\/\/my.clevelandclinic.org\/health\/diseases\/12100\u2010sickle\u2010cell\u2010disease. Accessed August 13 2025."},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010202491"},{"key":"e_1_2_13_9_1","volume-title":"Addressing sickle cell disease: a strategic plan and blueprint for action","author":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action","year":"2020"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19523"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24255"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.2010.08523.x"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009049"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400402"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063\u2010023\u201007649\u20107"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/13860291251357796"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.4103\/sja.SJA_543_18"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.2307\/2529786"},{"key":"e_1_2_13_19_1","unstructured":"(SQHA) QHS.What are the predictors of adherence to antihypertensive treatment. Available from:https:\/\/sqha2.hypertension.qc.ca\/quels\u2010sont\u2010les\u2010predicteurs\u2010de\u2010ladherence\u2010au\u2010traitement\u2010antihypertenseur\/. Accessed October 1 2025."},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12245"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014555"},{"key":"e_1_2_13_22_1","unstructured":"U.S. Department of Health and Human Services NCI.Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available from:https:\/\/dctd.cancer.gov\/research\/ctep\u2010trials\/for\u2010sites\/adverse\u2010events\/ctcae\u2010v5x7.pdf. Accessed October 1 2025."},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.11613\/bm.2014.022"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70622","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:04:00Z","timestamp":1789193040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/bjh.70622"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70622","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"2026-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}